Gerhard Behre
Leipzig University
34 Papers
102 Citations
Gerhard Behre is an academic researcher from Leipzig University. The author has contributed to research in topics: Myeloid leukemia & Hematopoietic stem cell transplantation. The author has an hindex of 14, co-authored 34 publications.
Chat about Author
Papers
Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Sibylle C. Mellinghoff,Jens Panse,Nael Alakel,Gerhard Behre,Dieter Buchheidt,Maximilian Christopeit,Justin Hasenkamp,Michael G. Kiehl,Michael Koldehoff,Stefan W. Krause,Nicola Lehners,Marie von Lilienfeld-Toal,Annika Y Löhnert,Georg Maschmeyer,Daniel Teschner,Andrew J. Ullmann,Olaf Penack,Markus Ruhnke,Karin Mayer,Helmut Ostermann,Hans-H. Wolf,Oliver A. Cornely +21 more
TL;DR: Prophylaxis should be performed with posaconazole delayed release tablets during remission induction chemotherapy for AML and MDS and can be used when the oral route is contraindicated or not feasible, as well as in cases of clinical failure such as breakthrough IFI.
Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients
Marius Bill,Juliane Grimm,Madlen Jentzsch,Laura Kloss,Karoline Goldmann,Julia Schulz,Stefanie Beinicke,Janine Häntschel,Michael Cross,Vladan Vucinic,Wolfram Pönisch,Gerhard Behre,Georg-Nikolaus Franke,Thoralf Lange,Dietger Niederwieser,Sebastian Schwind +15 more
TL;DR: Positive mutated NPM1 measurable residual disease status determined by ddPCR before allogeneic stem cell transplantation is associated with worse prognosis independent of other known prognostic markers—also for those receiving non-myeloablative conditioning.
71
PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia
Daniela Bräuer-Hartmann,Jens Uwe Hartmann,Alexander Arthur Wurm,Dennis Gerloff,Christiane Katzerke,Maria Vittoria Verga Falzacappa,Pier Giuseppe Pelicci,Carsten Müller-Tidow,Daniel G. Tenen,Daniel G. Tenen,Dietger Niederwieser,Gerhard Behre +11 more
TL;DR: Downregulation of the miR-181a/b gene cluster in APL blasts and NB4 leukemia cells upon ATRA treatment as a key event in the drug response is reported and RASSF1A is revealed as a pivotal element in the granulocytic differentiation program induced by ATRA inAPL.
Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma
Wolfram Pönisch,Bruno Holzvogt,Madlen Plötze,Marc Andrea,Malvina Bourgeois,Simone Heyn,Thomas Zehrfeld,Doreen Hammerschmidt,Maik Schwarz,Thomas Edelmann,Cornelia Becker,Franz Albert Hoffmann,Andreas Schwarzer,Ute Kreibich,Kerstin Gutsche,Kolja Reifenrath,Cornelia Winkelmann,Rainer Krahl,Yvonne Remane,Evelin Hennig,Thomas Schliwa,Tom H. Lindner,Thorsten Kaiser,Vladan Vucinic,Gerhard Behre,Dietger Niederwieser +25 more
TL;DR: These results indicate that this BPV combination is feasible, effective and well tolerated in patients with newly diagnosed MM and normal or impaired renal function.
30
MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia.
Jens-Uwe Hartmann,Daniela Bräuer-Hartmann,Miroslava Kardosova,Alexander Arthur Wurm,Franziska Wilke,Cindy Schödel,Dennis Gerloff,Christiane Katzerke,Rosanna H.E. Krakowsky,Carolina Yaeko Namasu,Marius Bill,Sebastian Schwind,Carsten Müller-Tidow,Dietger Niederwieser,Meritxell Alberich-Jorda,Gerhard Behre +15 more
TL;DR: In this paper, a previously unrecognized function of microRNAs (miRNAs) in granulopoiesis was reported, which may be useful as a prognostic and therapeutic factor in AML therapy.